Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ProPhase Labs (PRPH) Share Price
Media headlines about ProPhase Labs (NASDAQ:PRPH) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProPhase Labs earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5825671601561 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ProPhase Labs (PRPH) opened at 2.03 on Wednesday. The firm’s 50-day moving average price is $2.05 and its 200 day moving average price is $2.02. ProPhase Labs has a 52-week low of $1.49 and a 52-week high of $2.45. The company has a market cap of $34.83 million, a PE ratio of 0.81 and a beta of 0.07.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ProPhase Labs (PRPH) Share Price” was reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/09/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-prophase-labs-prph-share-price.html.
About ProPhase Labs
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.